Atai Life Sciences Stock Surges 15% on Promising Antidepressant Trial Results

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-24 00:59:01

BTCCSquare news:

Atai Life Sciences (ATAI) shares soared nearly 15% Tuesday, defying a 0.6% market downturn, after revealing positive phase 2a results for its experimental antidepressant BPL-003. The open-label study demonstrated rapid, clinically meaningful effects lasting up to three months in treatment-resistant depression patients.

The biotech firm, collaborating with UK-based Beckley Psytech, reported continued efficacy at higher doses as measured by the MADRS scale. This marks the second consecutive successful trial for the compound, positioning it for potential phase 3 advancement pending regulatory discussions.

By:

Log in to Reply

Lithium Americas Soars 90% After U.S. Acquires 10% Stake Under Trump-Brokered Deal

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.